BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32181817)

  • 1. Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.
    Li L; Mitra A; Cui K; Zhao B; Choi S; Lee JY; Stamos DB; El-Khoury D; Warzecha C; Pfeifer K; Hardwick J; Zhao K; Venters B; Davé UP; Love PE
    Blood; 2020 Jun; 135(25):2252-2265. PubMed ID: 32181817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.
    Shields BJ; Alserihi R; Nasa C; Bogue C; Alexander WS; McCormack MP
    Leukemia; 2015 Apr; 29(4):927-38. PubMed ID: 25283843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
    McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
    Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.
    Shields BJ; Slape CI; Vo N; Jackson JT; Pliego-Zamora A; Ranasinghe H; Shi W; Curtis DJ; McCormack MP
    Leukemia; 2019 Aug; 33(8):1868-1880. PubMed ID: 30700838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal.
    McCormack MP; Young LF; Vasudevan S; de Graaf CA; Codrington R; Rabbitts TH; Jane SM; Curtis DJ
    Science; 2010 Feb; 327(5967):879-83. PubMed ID: 20093438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
    Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
    Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.
    Goossens S; Wang J; Tremblay CS; De Medts J; T'Sas S; Nguyen T; Saw J; Haigh K; Curtis DJ; Van Vlierberghe P; Berx G; Taghon T; Haigh JJ
    Haematologica; 2019 Aug; 104(8):1608-1616. PubMed ID: 30679322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LMO2 promotes the development of AML through interaction with transcription co-regulator LDB1.
    Lu L; Wang J; Fang F; Guo A; Jiang S; Tao Y; Zhang Y; Li Y; Zhang K; Zhang Z; Zhuo R; Chu X; Li X; Tian Y; Ma L; Sang X; Chen Y; Yu J; Yang Y; Cao H; Gao J; Lu J; Hu S; Pan J; He H
    Cell Death Dis; 2023 Aug; 14(8):518. PubMed ID: 37573405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
    Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
    PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
    Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
    Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition.
    Abdulla HD; Alserihi R; Flensburg C; Abeysekera W; Luo MX; Gray DHD; Liu X; Smyth GK; Alexander WS; Majewski IJ; McCormack MP
    J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36920307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
    Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
    Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
    Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
    PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.
    Layer JH; Alford CE; McDonald WH; Davé UP
    Mol Cell Biol; 2016 Feb; 36(3):488-506. PubMed ID: 26598604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels.
    Miyashita K; Kitajima K; Goyama S; Kitamura T; Hara T
    Biochem Biophys Res Commun; 2018 Jan; 495(3):2310-2316. PubMed ID: 29278703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation.
    Visvader JE; Mao X; Fujiwara Y; Hahm K; Orkin SH
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13707-12. PubMed ID: 9391090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.
    McCormack MP; Forster A; Drynan L; Pannell R; Rabbitts TH
    Mol Cell Biol; 2003 Dec; 23(24):9003-13. PubMed ID: 14645513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.
    El Omari K; Hoosdally SJ; Tuladhar K; Karia D; Vyas P; Patient R; Porcher C; Mancini EJ
    Blood; 2011 Feb; 117(7):2146-56. PubMed ID: 21076045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements.
    Homminga I; Vuerhard MJ; Langerak AW; Buijs-Gladdines J; Pieters R; Meijerink JP
    Haematologica; 2012 Feb; 97(2):258-61. PubMed ID: 22058201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.
    Zhou S; Fatima S; Ma Z; Wang YD; Lu T; Janke LJ; Du Y; Sorrentino BP
    Mol Ther; 2016 Jun; 24(6):1090-1099. PubMed ID: 26957223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.